William Blair Investment Management LLC Sells 29,064 Shares of PTC Therapeutics, Inc. $PTCT

William Blair Investment Management LLC lessened its stake in PTC Therapeutics, Inc. (NASDAQ:PTCT – Free Report) by 1.7% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,693,624 shares of the biopharmaceutical company’s stock after selling 29,064 shares during the period. William Blair Investment Management LLC owned about 2.03% of PTC Therapeutics worth $109,713,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. Rock Springs Capital Management LP lifted its position in shares of PTC Therapeutics by 161.5% during the first quarter. Rock Springs Capital Management LP now owns 161,798 shares of the biopharmaceutical company’s stock worth $11,023,000 after purchasing an additional 99,919 shares during the last quarter. Parkman Healthcare Partners LLC acquired a new position in PTC Therapeutics in the second quarter worth about $35,539,000. VIRGINIA RETIREMENT SYSTEMS ET Al bought a new stake in PTC Therapeutics in the second quarter valued at about $2,321,000. Janus Henderson Group PLC increased its holdings in PTC Therapeutics by 48.3% in the first quarter. Janus Henderson Group PLC now owns 7,193,433 shares of the biopharmaceutical company’s stock valued at $489,997,000 after buying an additional 2,342,101 shares during the last quarter. Finally, The Manufacturers Life Insurance Company bought a new stake in PTC Therapeutics in the second quarter valued at about $36,050,000.

PTC Therapeutics Stock Performance

Shares of PTC Therapeutics stock opened at $63.49 on Monday. The stock has a market capitalization of $5.30 billion, a price-to-earnings ratio of -45.35, a PEG ratio of 4.66 and a beta of 0.52. PTC Therapeutics, Inc. has a twelve month low of $58.80 and a twelve month high of $90.87. The business’s 50 day simple moving average is $64.12 and its 200-day simple moving average is $70.27.

PTC Therapeutics (NASDAQ:PTCT – Get Free Report) last released its quarterly earnings data on Thursday, October 29th. The biopharmaceutical company reported ($0.62) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.14 by ($0.76). The company had revenue of $357.81 million during the quarter, compared to analyst estimates of $306.43 million. PTC Therapeutics’s revenue for the quarter was up 69.6% on a year-over-year basis. During the same period in the prior year, the company earned $0.20 EPS. Sell-side analysts predict that PTC Therapeutics, Inc. will post 0.49 earnings per share for the current year.

PTC Therapeutics declared that its board has initiated a share repurchase plan on Tuesday, November 3rd that permits the company to repurchase $500 million in shares. This buyback authorization permits the biopharmaceutical company to repurchase up to 9.8% of its stock through open market purchases. Share buyback plans are typically an indication that the company’s board of directors believes its stock is undervalued.

Wall Street Analyst Weigh In

Several analysts have issued reports on PTCT shares. Royal Bank Of Canada upped their price objective on PTC Therapeutics from $75.00 to $77.00 and gave the company a “sector perform” rating in a research note on Friday, October 30th. Citigroup lifted their target price on PTC Therapeutics from $108.00 to $109.00 and gave the stock a “buy” rating in a research report on Monday, November 2nd. Zacks Research downgraded PTC Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday, August 6th. Raymond James Financial set a $106.00 price target on PTC Therapeutics in a report on Tuesday, October 20th. Finally, Morgan Stanley upped their price target on PTC Therapeutics from $93.00 to $104.00 and gave the company an “overweight” rating in a research report on Friday, July 31st. One investment analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $99.23.

Read Our Latest Report on PTCT

Insider Buying and Selling at PTC Therapeutics

In other PTC Therapeutics news, VP Mark Boulding sold 435 shares of the firm’s stock in a transaction on Tuesday, October 6th. The stock was sold at an average price of $64.16, for a total value of $27,909.60. Following the sale, the vice president directly owned 105,272 shares in the company, valued at approximately $6,754,251.52. This trade represents a 0.41% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Michael Schmertzler sold 2,500 shares of the business’s stock in a transaction on Wednesday, October 14th. The shares were sold at an average price of $59.61, for a total transaction of $149,025.00. Following the transaction, the director directly owned 1,291,594 shares of the company’s stock, valued at approximately $76,991,918.34. This trade represents a 0.19% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 64,265 shares of company stock worth $4,412,399. 5.30% of the stock is owned by insiders.

PTC Therapeutics Profile

(Free Report)

PTC Therapeutics is a biopharmaceutical company focused on discovering, developing and commercializing medicines for rare diseases. Founded in 1998 and headquartered in Warren, New Jersey, the company works across several therapeutic areas, including genetic and neurological disorders. Its products include Kebilidi (eladocagene exuparvovec), a gene therapy for aromatic L-amino acid decarboxylase deficiency, and Sephience (sepiapterin), a treatment for phenylketonuria. PTC has also developed medicines for Duchenne muscular dystrophy, including ataluren, marketed as Translarna in some regions.

Featured Stories

Want to see what other hedge funds are holding PTCT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PTC Therapeutics, Inc. (NASDAQ:PTCT – Free Report).

Institutional Ownership by Quarter for PTC Therapeutics (NASDAQ:PTCT)

Receive News & Ratings for PTC Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PTC Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.